Diagnostic Accuracy of a New Cardiac Electrical Biomarker for Detection of Electrocardiogram Changes Suggestive of Acute Myocardial Ischemic Injury
Objective A new cardiac “electrical” biomarker (CEB) for detection of 12‐lead electrocardiogram (ECG) changes indicative of acute myocardial ischemic injury has been identified. Objective was to test CEB diagnostic accuracy. Methods This is a blinded, observational retrospective case‐control, noninf...
Saved in:
| Published in | Annals of noninvasive electrocardiology Vol. 19; no. 2; pp. 129 - 144 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Blackwell Publishing Ltd
01.03.2014
John Wiley & Sons, Inc John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1082-720X 1542-474X 1542-474X |
| DOI | 10.1111/anec.12109 |
Cover
| Summary: | Objective
A new cardiac “electrical” biomarker (CEB) for detection of 12‐lead electrocardiogram (ECG) changes indicative of acute myocardial ischemic injury has been identified. Objective was to test CEB diagnostic accuracy.
Methods
This is a blinded, observational retrospective case‐control, noninferiority study. A total of 508 ECGs obtained from archived digital databases were interpreted by cardiologist and emergency physician (EP) blinded reference standards for presence of acute myocardial ischemic injury. CEB was constructed from three ECG cardiac monitoring leads using nonlinear modeling. Comparative active controls included ST voltage changes (J‐point, ST area under curve) and a computerized ECG interpretive algorithm (ECGI). Training set of 141 ECGs identified CEB cutoffs by receiver‐operating‐characteristic (ROC) analysis. Test set of 367 ECGs was analyzed for validation. Poor‐quality ECGs were excluded. Sensitivity, specificity, and negative and positive predictive values were calculated with 95% confidence intervals. Adjudication was performed by consensus.
Results
CEB demonstrated noninferiority to all active controls by hypothesis testing. CEB adjudication demonstrated 85.3–94.4% sensitivity, 92.5–93.0% specificity, 93.8–98.6% negative predictive value, and 74.6–83.5% positive predictive value. CEB was superior against all active controls in EP analysis, and against ST area under curve and ECGI by cardiologist.
Conclusion
CEB detects acute myocardial ischemic injury with high diagnostic accuracy. CEB is instantly constructed from three ECG leads on the cardiac monitor and displayed instantly allowing immediate cost‐effective identification of patients with acute ischemic injury during cardiac rhythm monitoring. |
|---|---|
| Bibliography: | istex:CA455FD12F4A2E2FBBAB8C192A0D6A5B8F5D0894 ark:/67375/WNG-PRXJSHV1-3 ArticleID:ANEC12109 Funding Sources/Disclosures Awards Portions of this study were presented at the Society for Critical Care Medicine 40th Annual Critical Care Congress, San Diego, California, January 16, 2011, for which it won the first place research award. Annual Scientific Sessions, May 7, 1996, Denver, Colorado, for which it won first prize as the Best Technology Presentation. Dr. David M. Schreck owns a significant nonmajority interest in VectraCor that constitutes greater than 5% of the entity. VectraCor is the medical device company that has developed the technology for the derivation of the n‐lead ECG and the cardiac electrical biomarker. Portions of the this study were presented at the Society for Academic Emergency Medicine This study was unfunded. Portions of this study were presented at the American College of Emergency Physicians Scientific Assembly September 14–16, 1992, Seattle, Washington, for which it received first prize award for the Best Educational Exhibit. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ISSN: | 1082-720X 1542-474X 1542-474X |
| DOI: | 10.1111/anec.12109 |